PKC‐dependent regulation of the receptor locus dominates functional consequences of cysteinyl leukotriene type 1 receptor activation
Open Access
- 28 March 2007
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 21 (10) , 2335-2342
Abstract
Leukotrienes are important lipid mediators of asthma that contribute to airway inflammation and bronchoconstriction. Critical mechanisms for physiological regulation of the main G protein‐coupled receptor (GPCR) mediating the leukotriene responses in asthma, cysteinyl leukotriene type 1 receptor (CysLT1R), have not been delineated. Although desen‐sitization of GPCRs is a well‐established phenomenon, studies demonstrating its physiological relevance are lacking. Here, we demonstrate that relief of PKC‐mediated desensitization of endogenous CysLT1Rs augments multiple LTD 4 ‐stimulated cellular functions, with associated increases in intracellular signaling events. In analyses of airway smooth muscle contraction ex vivo , PKC inhibition augmented LTD4‐stimulated contraction, and increased phosphoinositide hydrolysis and calcium flux in both murine and human airway smooth muscle cells. Similarly, for human monocytes, PKC inhibition augmented LTD4‐stimulated calcium flux and cell migration assessed in transwell chamber experiments and also augmented LTD4‐induced production of monocyte chemotactic protein assessed by ELISA. In contrast, PKC inhibition had no effect or slightly attenuated these cell functions and signaling events promoted by other receptor agonists, suggesting that despite antithetical effects on downstream events, desensitization of the CysLT1R is the principal mechanism by which PKC regulates the functional consequences of CysLTIR activation.—Deshpande, D. A., Pascual, R. M., Wang, S.‐W., Eckman, D. M., Riemer, E. C., Funk, C. D., Penn, R. B. PKC‐dependent regulation of the receptor locus dominates functional consequences of cysteinyl leukotriene type 1 receptor activation. FASEB J. 21, 2335–2342 (2007)Keywords
Funding Information
- National Institutes of Health (AI059755)
- Canadian Institutes of Health Research (MOP-68930)
This publication has 36 references indexed in Scilit:
- Leukotriene modifiers as potential therapeutics for cardiovascular diseaseNature Reviews Drug Discovery, 2005
- Regulation of Cysteinyl Leukotriene Type 1 Receptor Internalization and SignalingJournal of Biological Chemistry, 2005
- Transgenic smooth muscle expression of the human CysLT1receptor induces enhanced responsiveness of murine airways to leukotriene D4American Journal of Physiology-Lung Cellular and Molecular Physiology, 2004
- Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosisProceedings of the National Academy of Sciences, 2004
- Regulation of G Protein-Coupled Receptor KinasesTrends in Cardiovascular Medicine, 2000
- Characterization of the human cysteinyl leukotriene CysLT1 receptorNature, 1999
- Control of Myocardial Contractile Function by the Level of β-Adrenergic Receptor Kinase 1 in Gene-targeted MiceJournal of Biological Chemistry, 1998
- Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted miceProceedings of the National Academy of Sciences, 1998
- Cardiac Function in Mice Overexpressing the β-Adrenergic Receptor Kinase or a βARK InhibitorScience, 1995
- A human airway smooth muscle cell line that retains physiological responsivenessAmerican Journal of Physiology-Cell Physiology, 1989